Data from multiple sources - Curated by EPG Health - Last updated 06 June 2017
Added 3 days ago Drug news
FDA accepts supplemental application to expand indication of Cinryze to children aged 6 years and older with hereditary angioedema.- Shire.
The FDA has accepted the Cinryze (C1 esterase inhibitor [human]), from Shire, supplemental Biologics License Application (sBLA) to expand the...
Added 5 months ago Drug news
Phase III SAHARA study success for SHP 616 Liquid (subcutaneously administered C1 esterase inhibitor [human] Liquid for Injection) to treat Hereditary Angioedema.-Shire plc.
Shire plc announces positive topline Phase III results for the SAHARA study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover...
Added 7 months ago Drug news
FDA approves Haegarda (subcutaneous C1-esterase inhibitor) for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.-CSL Behring
The FDA has approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...
Added 5 years ago
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.
Added 8 months ago
Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders
Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...
Added 3 years ago
Risk factors for oral mucositis in children receiving hematopoietic cell transplantation for primary immunodeficiencies: A retrospective study
OM is a frequent complication for patients undergoing HSCT. The aim of this study was to evaluate the possible risk...
Added 4 years ago